MD Anderson cancer experts share discoveries at AACR Annual Meeting
A number of MD Anderson physicians and scientists chaired or co-chaired sessions and presented research, ranging from racial disparities in the quality of life of minority colorectal cancer patients to a potential druggable target for prostate cancer, at the American Association of Cancer Research Annual Meeting earlier this month in Washington, D.C.
In addition, Gordon Mills, M.D., Ph.D., chair of Systems Biology, was elected...
Evidence supports the need to raise the legal tobacco age
(Editor's note: This article was updated on April 9, 2019 to reflect new Texas legislation filed in 2019, similar legislation passed...
Neurofeedback reduces chemo-induced nerve damage
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
Breakthrough research targets immunotherapy resistance
Stories of immunotherapy’s success against metastatic melanoma in patients such as former President Jimmy Carter are well publicized, but the treatment doesn’t work for everyone.
In fact, checkpoint blockade drugs such as pembrolizumab and nivolumab, which inhibit protein molecules on T cells that keep the immune system from attacking tumors, only work for about one-third of patients.
Why do some tumors respond...
Drug outperforms chemo for treatment of acute lymphoblastic leukemia
The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia...
Advanced radiation technique shows promise for lung cancer treatment
An advanced form of image-guided radiation therapy known as intensity modulated proton therapy (IMPT) has shown early promise for the treatment...
MD Anderson scientists unraveling complexities of bile duct cancer
Extensive genomic analysis led by MD Anderson researchers has opened new avenues to explore in the treatment of a rare and tenaciously lethal...